Publications by authors named "Jules Harris"

Claim this Profile
A
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Gershon Y Locker, Stanley Hamilton, Jules Harris, John M Jessup, Nancy Kemeny

J Clin Oncol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282.
Minaxi Jhawer, Sridhar Mani, Myrto Lefkopoulou, Richard G Hahn, Jules Harris

Invest New Drugs· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival.
Roderick M Quiros, Geetha Rao, Janet Plate, Jules E Harris, Gregory J Brunn

Cancer· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
Janet M D Plate, Aileen E Plate, Susan Shott, Susan Bograd, Jules E Harris

Cancer Immunol Immunother· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer.
Janet M D Plate, Jules E Harris

J Cell Biochem· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
Howard A Burris, Saul Rivkin, Robert Reynolds, Jules Harris, Arnold Wax

Oncologist· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
Robert C Shepard, Donna E Levy, Jordan D Berlin, Keith Stuart, Jules E Harris

Oncology· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: an Eastern Cooperative Oncology Group study (EST 1285).
Kishan J Pandya, Myrto Lefkopoulou, Nicholas J Petrelli, David J Vaughn, Thomas J Smith, Jules E Harris

Oncology· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study.
Andrea N Leaf, Kathleen Propert, Chris Corcoran, Paul J Catalano, Donald L Trump, Jules E Harris

Med Oncol· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MK 886 functions as a radiomimetic agent: genomic responses related to oxidative stress, the cell cycle, proliferation and programmed cell death in Panc-1 cells.
Ken M Anderson, Waddah Alrefai, Colin Anderson, Philip Bonomi, Jules Harris

Adv Exp Med Biol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant and Neoadjuvant Therapies of Pancreatic Cancer: A Review.
Jules Harris, Howard Bruckner

Int J Gastrointest Cancer· January 2001

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis